Incruse Ellipta 62.5 mcg/INHAL Dry Powder Inhaler, 30 Blisters
RxNorm 1539885
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1539885 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Incruse Ellipta 62.5 mcg/INHAL Dry Powder Inhaler, 30 Blisters.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
30 ACTUAT umeclidinium 0.0625 mg/ACTUAT Dry Powder Inhaler [Incruse]
(Atom ID: 6343458)
SYPrescribable
Synonym (SY):
Incruse Ellipta (umeclidinium 62.5 mcg) per ACTUAT Dry Powder Inhaler, 30 ACTUAT
(Atom ID: 6343462)
PSNPrescribable
Prescribable Name (PSN):
Incruse Ellipta 62.5 mcg/INHAL Dry Powder Inhaler, 30 Blisters
(Atom ID: 6372329)
SYPrescribable
Synonym (SY):
Incruse Ellipta 62.5 mcg/INHAL Dry Powder Inhaler, 30 Blisters
(Atom ID: 6815658)
Patient Education
Umeclidinium Oral Inhalation
Umeclidinium oral inhalation is used in adults to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). Umeclidinium inhalation is in a class of medications called anticholinergics. It works by relaxing and opening air passages in the lungs, making it easier to breathe.
[Learn More]
* Please review the disclaimer below.